

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 03/014739 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/543**,  
27/447

Mastri, 17, I-47014 Meldola (IT). **GUERRIERI, Roberto**  
[IT/IT]; Via Calari, 19/2, I-40122 Bologna (IT).

(21) International Application Number: PCT/IT02/00524

(74) Agents: **JORIO, Paolo** et al.; Studio Torta S.r.l., Via  
Viotti, 9, I-10121 Torino (IT).

(22) International Filing Date: 7 August 2002 (07.08.2002)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
TO01A000801 7 August 2001 (07.08.2001) IT

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **SILICON  
BIOSYSTEMS S.R.L.** [IT/IT]; Viale Bricolani, 3, I-40138  
Bologna (IT).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CI, CG, CL, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **MANARESI, Nicolò**  
[IT/IT]; Via Santo Stefano, 132, I-40138 Bologna (IT).  
**MEDORO, Gianni** [IT/IT]; Via Ugo Lamalfa, 3, I-71049  
Trinitapoli (IT). **ALTOMARE, Luigi** [IT/IT]; Via Misa,  
6, I-40139 Bologna (IT). **TARTAGNI, Marco** [IT/IT]; Via

Published:

— with international search report

[Continued on next page]

(54) Title: METHOD AND DEVICE FOR INTEGRATED BIOMOLECULAR ANALYSES



(57) Abstract: A method whereby first biological entities are recognized by way of second biological entities able to bind to the first (or the first to the second), including the steps of binding first biological entities to a surface comprising an array of first electrodes selectively energizable and addressable at least in part, positioned facing at least one second electrode, bringing the second biological entities into contact with the first, these second biological entities and possibly the first being moved by means of dielectrophoretic cages generated between the electrodes, and sensing any binding activity between at least a portion of the first and of the second biological entities, preferably utilizing radiation at a first frequency to excite fluorophore groups bound to the second biological entities and detecting the emission of fluorescence at a second frequency by means of optical sensors integrated into the electrodes, the biological entities preferably being concentrated on the electrodes by the fusion of dielectrophoretic cages.

WO 03/014739 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## METHOD AND DEVICE FOR INTEGRATED BIOMOLECULAR ANALYSES

5        TECHNICAL FIELD

The present invention relates to a method of molecular biological analysis utilizing dielectrophoretic forces to manipulate biological components advantageously and with high processivity.

10 In particular, the method disclosed can be used to check the binding force between proteins and/or verify the presence and quantity of proteins in a sample, to assemble arrays of test points, to check the concentration of the proteins being tested, and, 15 optionally, to observe the results with the aid of sensors integrated into the test device. The invention relates similarly to a device for implementation of the method thus outlined, equipped with the aforementioned integrated sensors.

20        BACKGROUND ART

A great many immunological methods have been developed in recent years allowing the determination of antigens and antibodies, both for purely scientific and for diagnostic purposes.

25        Immunoassays

Immunological tests, or immunoassays, utilize a number

of notably powerful methods for identifying and measuring antigens and antibodies. Specific antibodies are available for an increasing number of antigens, soluble, immobilized (on plates, resins or membranes), conjugated and otherwise. Moreover, with the range of systems for analyzing antigen-antibody complexes becoming steadily wider, and their sensitivity continuing to be improved, the potential and the range of applications for immunological reactions and techniques have been extended conspicuously. In the case of soluble antigens and antibodies, assays are based on the labelling of one of the reagents, on the formation and precipitation of immunocomplexes, or on the measurement of an effector function expressed by the antibody.

For some time, the most sensitive system available was radioimmunoassay (RIA), developed by Yalow and Benson in 1960. This method betrays numerous drawbacks at all events, including the need for special equipment, also for special precautions against radiation (and for specially trained staff), and the limited average life of the radioactive isotopes used for labelling purposes. Such constraints soon led to the notion of replacing isotopes with enzymes as the



labelling medium. The first studies on Enzyme Immunoassay (EIA) were conducted by Schuurs et al. and disclosed in a series of patents: U.S. Pat. Nos. 3,654,090; 3,791,932 and successive references. EIA methods include ELISA (Enzyme-Linked Immunoabsorbent Assay) and its numerous variations, which currently are the methods of choice in the art fields of research and diagnostics. EIA-ELISA procedures are categorized as competitive and non-competitive, which in turn can be homogeneous or heterogeneous. Whilst homogeneous assays require no physical separation, heterogeneous assays require separation of the free antigen fraction from the fraction bound to the antibody, obtained by means of a solid phase system consisting generally in polystyrene, cellulose or nylon substrates to which the antibodies are bound. The substrates are usually 96- and 384-well microtiter plates or microstrips having 8, 12 and 16 wells, though they can also consist in single elements known as microbeads, on which the antigens or antibodies are immobilized. Competitive enzyme immunoassays are those where the antibody is present in a limited concentration. In non-competitive or immunometric assays, on the other hand, a notable excess of the antibody is used, conjugated with the

enzyme, so as to maximize the antigen signal. Among non-competitive enzymatic immunoassays, the system most widely adopted involves capturing antigens from the sample on the walls of microsites coated with antibodies, generally monoclonal (mAb). The captured antigen is marked by coating it with a second layer of specific antibodies (secondary antibodies) with or without further amplification steps. The secondary antibody is often conjugated with an enzyme, the conversion of the enzyme demonstrating the presence of a given antigen: this is known as a sandwich ELISA assay.

With a wide range of substrates available for marker enzymes, it is possible to choose between different detection methods. The substrates are reagents that allow of displaying, qualifying and/or quantifying an analyte of interest in an enzyme immunoassay. Substrates can be chromogenic, chemiluminescent or fluorescent. Chromogenic substrates produce a coloured compound that can be identified visually and quantified with a spectrophotometer. Chemiluminescent substrates produce light that can be measured with a luminometer or recorded permanently on X-ray film. Fluorescent substrates on the other hand

emit fluorescence that is measured with a fluorometer. Chromogenic and chemiluminescent substrates are excellent media for the detection of conjugates labelled with enzymes bound indirectly to a solid support. The enzymes commonly used for the purpose are peroxidase, generally Horse Radish Peroxidase (HRP), which catalyzes the fission of  $H_2O_2$ , Alkaline Phosphatase (AP), which removes the phosphate from phosphorylate molecules, and  $\beta$ -galactosidase ( $\beta$ -Gal), which hydrolyzes lactose. The conversion of numerous substrate molecules by a single enzyme molecule produces a notable amplification of the signal, though if a luminogenic or fluorogenic substrate is used, the signal/mass is still greater, comparable to that obtained with Radioimmunoassays.

EIA methods are powerful, but affected by the serious limitation of low productivity (given the difficulty of conducting significant numbers of analyses in parallel), due mainly to the scant possibilities for integration afforded by the various items of equipment needed to carry out the procedure. This makes it all but impossible to process thousands of samples simultaneously or at least in a short time, whereas speed is becoming more and more a fundamental

aspect of modern research and diagnostics. In addition, EIA can involve a relatively heavy consumption of costly reagents.

Labelled microbeads

5 Not least in order to overcome the aforementioned drawbacks, the use of microbeads labelled selectively employing various fluorescence methods is gaining more and more importance in the art field of biotechnologies. Especially pertinent in this field are  
10 the following patents:

WO 00/68692 in the name of *Quantum Dot Corporation*, which discloses various assay methods utilizing semiconductor nanocrystals, each emitting at distinct wavelengths, as specific markers for different  
15 microbeads;

WO 01/13120 A1 in the name of *Luminex Corporation*, which discloses microparticles emitting multiple fluorescence signals and methods for their use in a cytofluorometric system.

20 Molecular sensors based on surface plasmon resonance

US Patent 5,641,640 in the name of *BIACore AB*, discloses a system for the analysis of biological samples using surface plasmon resonance. Molecules of a

sample held in suspension are directed into a chamber, of which the surface carries immobilized molecules potentially capable of binding with those of the sample. The binding of the molecules is sensed by indirect measurement of the variation in the refraction index caused by the binding of the molecules with the surface, observing the reflection from the surface of a suitable light source.

#### Dielectrophoresis

Dielectrophoresis relates to the physical phenomenon whereby dielectric particles subject to spatially non-uniform d.c. and/or a.c. electric fields undergo a net force directed toward those regions of space characterized by increasing (pDEP) or decreasing (nDEP) field strength. If the strength of the resulting forces is comparable to the force of gravity, it is possible in essence to create an equilibrium of forces enabling the levitation of small particles. The strength, direction and orientation of the dielectrophoretic force are heavily dependent on the dielectric and conductive properties of the body and of the medium in which it is immersed, and these properties in turn vary with frequency.

Studies analyzing the effects of dielectrophoretic

forces on particles (the term "particles" is used hereinafter to indicate dielectrophoretically manipulated bodies or elements) consisting in biological entities (the term "biological entities" is used hereinafter to indicate cells and microorganisms, or parts thereof, namely DNA, proteins, etc.) or artificial objects consisting of inorganic matter, have suggested for some time the notion of exploiting these forces as a means of selecting a particular body from a sample containing a plurality of microorganisms, characterizing the physical properties of microorganisms and in general allowing their manipulation. Accordingly, it has been found advantageous to utilize systems comparable in size to those of the microorganisms being manipulated, and thus reduce the magnitude of the voltages used to create the field distributions needed to reveal the aforementioned effects.

Particles exposed to the phenomenon of dielectrophoresis are subject to forces dependent on the volume of the particle; this being the case, it has been assumed for some time that there must be a lower limit for particle size, beneath which dielectrophoretic force would be defeated by Brownian

movement. It was considered that there would be a need for electric fields of magnitude such that local warming of the fluid would increase local flow and effectively prevent dielectrophoretic manipulation.

5 Pohl (1978) speculated that the electric fields needed to trap particles smaller than 500nm subject to Brownian movement would be too strong. The first group to overcome this obstacle was that of Washizu (Washizu et al., Trans. Ind. Appl. 30:835-843, 1994), who used

10 positive dielectrophoresis to precipitate small proteins down to 25kDa. This lowering of the threshold was favoured by improvements in electrode manufacturing technologies, notably the use of electron beams in manufacture. Thereafter, Fuhr et al. (Fuhr, 1995, Proc.

15 St Andrews Meeting of Society for Experimental Biology p.77; Mueller et al., 1996, J. Phys. D: Appl. Phys. vol.29:340-349) and Green et al. (Green et al., 1995, Proc. St Andrews Meeting of Society for Experimental Biology p.77; Green et al., 1997, J. Biochem. Biophys.

20 Methods vol.35:89-102) demonstrated that viruses of 100 nm diameter could be manipulated employing negative dielectrophoresis. It was also shown that latex microbeads of 14 nm diameter could be trapped both with positive and with negative dielectrophoresis (Mueller

et al., 1996, J. Phys. D: Appl. Phys. vol.29:340-349).  
Subsequent studies showed that 68 kDa molecules of the  
protein avidin can be concentrated from solution using  
both positive and negative dielectrophoresis (Bakewell  
5 et al., 1998, Proc. 20th Ann. Int. Conf. IEEE Eng. Med.  
Biol. Soc. 20, 1079-1082).

Patent application PCT/WO 00/47322 discloses an  
apparatus and a method for manipulating particles  
utilizing closed dielectrophoretic potential cages,  
10 generated by singly and selectively addressable and  
mutually energizable adjacent electrodes making up an  
array.

Patent application PCT/WO 00/69565, filed by the  
same applicant, discloses a more efficient apparatus  
15 than that mentioned above and describes various methods  
of manipulating particles utilizing closed  
dielectrophoretic potential cages. The device described  
in this second PCT application is illustrated in figure  
1 and comprises two basic modules; the first such  
20 module consists in a regularly distributed array M1 of  
electrodes LIJ arranged on an insulating support (O1 in  
figure 1). The electrodes LIJ can be of any given  
conductive material, preference being given to metals  
compatible with electronic integration technology,



whereas the insulating medium O1 can be silicon oxide or any other insulating material.

The electrodes of the array can be of any given shape; in the example of figure 1, the electrodes are square. Each element of the array M1 consists in an electrode LIJ that is selectively addressable and energizable in such a way as to generate a dielectrophoretic cage S1 (figure 1) by means of which to manipulate a particle, generally a biological entity (BIO in figure 1), all of which occurring in a liquid or semi-liquid environment denoted L in figure 1.

The region beneath the electrodes (C in Fig. 1) can be occupied by sensing means, and more exactly integrated circuits incorporating sensors of various types, able to detect the presence of single particles in potential cages generated by the electrodes.

In a preferred embodiment, the second main module appears substantially as a single large electrode M2, covering the device in its entirety. Finally, the device may also include an upper support structure (O2 in figure 1). The simplest form for the second electrode M2 is that of a plain flat and uniform surface; other forms of greater or lesser complexity are possible (for example a grid of given mesh size

through which light is able to pass).

The most suitable material for the upper electrode M2 will be a transparent conductive material. Besides allowing the inclusion of sensing circuits as outlined previously, this will also allow the use of traditional optical inspection means (microscope and TV camera) located above the device.

Among the singular aspects of the invention disclosed in patent application PCT PCT/WO 00/69565, parts of which are incorporated into the present specification where necessary for reference purposes, is that the one substrate can accommodate both the elements capable of manipulating the particles (biological entities), and the sensing devices.

DISCLOSURE OF INVENTION

The object of the present invention is to overcome the drawbacks inherent in the prior art methods outlined above for conducting biomolecular tests on biological entities (cells, microorganisms or parts thereof, in particular oligonucleotides, proteins or parts thereof) in such a way that these tests can be carried out swiftly, efficiently and economically, with precision and high processivity, using smaller quantities of reagents and especially of costly

reagents, namely monospecific antibodies, labelled antibodies and substrates.

Here and in the following description, the term "protein" is used to indicate a molecular chain of amino acids bound by peptide bonds; the term does not refer to a specific length, and accordingly, the commonly used terms "polypeptide", "peptide" and "oligopeptide" are also included in the definition. Also included are post-translational modifications of protein such as glycosilations, acetylations, phosphorylations and the like. Moreover, the term protein likewise includes protein fragments, analogues, mutated or variant proteins, fusion proteins, and so forth.

Just as the term antibody can be taken, where not explicitly stated, to mean antibodies obtained from polyclonal and/or monoclonal preparations, it can also be taken to mean chimeric antibodies,  $F(ab')_2$  and  $F(ab)$  fragments,  $F_v$  molecules including single chain ( $sF_v$ ), dimeric and trimeric constructs of antibody fragments and any fragment obtained from these and similar molecules, where these happen to maintain the specific binding properties of the original antibody molecule.

In the light of the foregoing definitions, one

object of the present invention in particular is to exploit the potential afforded by the device of patent application PCT/WO 00/69565 in providing a method of conducting integrated biomolecular analysis on a biological sample including unknown biological entities, for example specific proteins or antigens or specific antibodies, by means of known biological entities, typically antibodies, or natural or synthetic proteins, such as can be run with a high level of automation and in parallel, if necessary, on a high number of samples, or on a significant number of different biological entities in one sample.

The stated objects are realized in a method according to the present invention for conducting integrated biomolecular analyses on a biological sample including unknown biological entities, with the aid of known biological entities capable of binding to the unknown biological entities, comprising the steps of immobilizing first biological entities directly or indirectly on a support, bringing second biological entities into contact with the first and detecting any binding activity between at least a proportion of the first biological entities and at least a proportion of the second biological entities; the first or second

biological entities being the unknown entities and the second or first biological entities being the known entities; characterized:

(A) - in that the support is provided by a surface  
5 consisting in an array of first electrodes, selectively energizable and addressable at least in part, disposed facing and distanced by means of a spacer from at least one second electrode, in such a manner that the second electrode, the spacer and the array of first electrodes  
10 combine to establish a test chamber such as will compass a liquid or semi-liquid environment in which closed dielectrophoretic cages are generated selectively by means of the first electrodes and the second electrode, for the purpose of trapping and  
15 moving at least the second biological entities in the chamber; and,

(B) - in that the surface is treated beforehand in such a way as to promote binding with the first biological entities at the first electrodes.

20 In particular, the immobilizing step comprises the single steps of:

a. introducing a suspension of the first biological entities into the chamber compassing the liquid or semi-liquid environment;

b. trapping and levitating the first biological entities within dielectrophoretic potential cages generated between selected first electrodes and the second electrode;

5 c. selectively directing the dielectrophoretic cages, with the first biological entities trapped inside them, toward selected first electrodes;

d. moving the cages in such a way as to promote binding between the first biological entities and the selected  
10 first electrodes, and consequently immobilizing the first biological entities on the electrodes, according to a predetermined patterning sequence.

One of the singular features of the method according to the invention consists moreover in the  
15 facility of concentrating antigens and/or antibodies involved in the analysis by attracting them into the dielectrophoretic cages. Other characterizing features of the method disclosed include the facility of generating protein microarrays, by dielectrophoretic  
20 manipulation of the protein population of interest, which can then be assayed to reveal their affinity with other proteins (antigens or antibodies). Moreover, the specificity of the antigen-antibody bond can be tested electronically by trying to separate the bound

proteins, seeking to draw one of them back into the dielectrophoretic cages by varying the particular force and/or frequency of the cage. The test can be monitored exploiting standard methods (fluorescence, luminescence or colour development) and employing optical sensors, which can be external (microscope and TV camera) or integrated into the device. Alternatively, it is possible to use a method exploiting capacitive sensors integrated into the device to observe the formation of antigen-antibody complexes.

A further object of the invention is to provide a device for conducting molecular biological analyses that will be notably compact, economical and reliable, while capable of fully automated operation and processing at high speed.

The stated object is realized according to the present invention in a device for molecular biological analyses performed with the aid of movable dielectrophoretic cages, comprising a surface afforded by an array of first electrodes selectively energizable and addressable at least in part and arranged on an insulating support; at least one second electrode positioned opposite and facing at least a part of the array of first electrodes; and a spacer serving to

distance the first electrodes from the at least one second electrode in such a way that the second electrode, the spacer and the array of first electrodes combine to establish a test chamber encompassing a liquid or semi-liquid environment; characterized in that it further comprises integrated optical sensors located beneath or in close proximity to at least one of the first electrodes; and in that the first electrodes comprise means by which to allow the transmission of electromagnetic radiation through the selfsame first electrodes and toward the optical sensors, operating in conjunction with means likewise forming part of the device and positioned to coincide with the first electrodes, by which radiation of a first predetermined wavelength is prevented from reaching the integrated optical sensors.

The advantages of the present invention are many and various.

The proposed method guarantees high sensitivity thanks to the possibility of concentrating the protein populations present in samples by attracting them selectively into the dielectrophoretic cages. This naturally signifies a saving in expenditure on reagents, as well as the facility of testing samples to



the limit of the detection potential afforded by standard methods.

Another singular advantage is the facility of verifying the specificity of the assay by way of an electronic antigen-antibody binding affinity check, which will eliminate false positives generated by possible cross-reactivity of the antibodies, a likelihood that cannot be excluded when handling thousands of antigens or antibodies together. This procedure also allows the stability of the antigen-antibody bond to be evaluated directly.

Complementing the high sensitivity obtainable with the method according to the present invention is an appreciable parallelism, given that the assay can be conducted on all the proteins in a single chamber rather than in a plurality of distinct, albeit very similar chambers. This, together with the high level of integration and feedback control achievable thanks to the automation allowed by the device and the method disclosed, means that any variability of response given by the assay due to system-related and/or accidental (operator) errors can be reduced to a minimum. Another advantage of the method is that of integrated sensing, which dispenses with the need for cumbersome

instruments (fluorometers, luminometers, etc.), which very often are not even associated with the test device. In the case of direct capacitive sensing, the experimenter avoids the need for labelling of the antibodies employing generally complex and costly procedures, to facilitate their identification. Likewise in the case of capacitive (indirect) labelling by means of microbeads, the procedure is particularly simple and applicable even to antigenic proteins.

10 In the case of a directly assembled protein array, exceptionally high density is achievable given that thousands of different proteins can be patterned on the electrodes of the device, which are spaced at a particularly fine pitch.

15 Other features and advantages of the invention will emerge more clearly from the following description of certain preferred embodiments illustrated by way of example, and implying no limitation, with the aid of the accompanying drawings.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic three-dimensional view showing part of a prior art device for the manipulation of a sample, which presents a modular structure composed of a support containing the electrodes, and a

lid;

Figure 2 illustrates one possible embodiment of an integrated optical sensor according to the present invention;

5        Figure 3 is a detailed step-by-step illustration of the method according to the invention;

Figure 4 illustrates a test procedure in which the sample containing the protein to be identified is immobilized on the electrodes, whereupon  
10       dielectrophoretic cages are generated above the electrodes;

Figure 5 shows another way of conducting an immunological assay according to the invention, in which there is no need to move the cages;

15       Figure 6 shows the spectral emission response of certain fluorescent molecules excited by a monochrome laser source emitting ultraviolet radiation at 405 nm;

Figure 7 illustrates an enlarged detail of figure 2, viewed schematically and representing a cross  
20       section through a planar MOS device associated with a well diffusion;

Figure 8 shows the spectral responses, calculated mathematically on the basis of the semiconductor device equations, interpolated with silicon related

experimental absorption data, of the two junctions of figure 7 for a typical CMOS device with detail definition of 0.7  $\mu\text{m}$ .

BEST MODE FOR CARRYING OUT THE INVENTION

5 With reference to figures 1 and 2, the device disclosed in patent application PCT WO/ 00/69565 (or a similar prior art device) is equipped according to the present invention with optical sensors capable of indicating the presence or absence of a biological  
10 element suspended in buffer solution within a dielectrophoretic cage. The electrode LIJ affords an opening, or window, of dimensions such as will not significantly affect the dielectrophoretic potential generated but nonetheless allow the passage of a  
15 certain amount of light radiation coming from a source external to device. The lid A1 is conventional in embodiment, fashioned from a semi-transparent conductive material in such a way that the transmission of the light radiation will not be impeded. The space  
20 beneath the window in the electrode LIJ is occupied by a silicon substrate C and, conventionally, a charge-storage junction photodiode CPH. The presence or absence of the biological element BIO will influence the amount of light radiation incident on the

photodiode, thus varying the quantity of charge accumulated over the integration time. The variations induced in stored charge status are revealed by a conventional charge amplifier CHA composed of: an operational amplifier, a feedback capacitor and a reference voltage VRE. The connection with the charge amplifier is obtained by enabling a suitable switch SW1, which might be located in the electrode LIJ. The photodiode and the charge amplifier are designed, applying prior art principles, to give a signal/noise ratio sufficient to verify the presence or absence of the biological particle.

The method according to the present invention is carried into effect, unless otherwise indicated, employing conventional chemical and biochemical procedures commonly used and widely documented in literature. The preferred procedure, though not exclusive and implying no limitation whatever, is that illustrated in figure 3.

The procedure begins with construction of the protein array to be tested; the array in the example of figure 3 is composed of antigen proteins, though these might equally well be antibody proteins. The sample containing a homogeneous population of antigen proteins

that will constitute the first element of the array is introduced into the device, and more exactly into the environment denoted L. The population is concentrated by attracting the molecules into a single dielectrophoretic cage. When the cage is moved, the antigen population trapped in the cage will move also, and this dielectrophoretic manipulation facility is used to route the antigens onto a selected electrode LIJ, which may be suitably functionalized (figure 3, step 1); in any event, the surface afforded by the array of electrodes LIJ will have been treated beforehand in a conventional manner so as to promote binding with the biological entities, in this instance antigens, at the selfsame electrodes LIJ. Lowering the dielectrophoretic cage, or deactivating the cage and exploiting diffusion, part of the molecules will bind to the electrode, through the agency of functionalized groups if included, whilst the unbound molecules are removed by raising or reactivating the cage and distancing it from the selected electrode (figure 3, step 2). This patterning step is repeated sequentially for all the antigens in the array (figure 3, step 3).

Alternatively, the protein array to be tested on the electrodes can be prepared using standard

microarray technology, such as inkjet.

At this point the sample containing the biological entities to be tested (mixture of antibodies) is introduced into the device (figure 3, step 4). The antibody population can be concentrated by attracting the molecules into a single dielectrophoretic cage (figure 3, step 5). The cage is manipulated in such a way as to offer the trapped antibodies to the first site (selected electrode LIJ or neighbourhood) where there are antigens present (figure 3, step 6). Thereupon, any antibodies in the sample that may be specific to the antigen bound to the site will now bind in their turn to the antigen, thereby confirming the presence of antibody proteins present in the sample, and conceivably the quantity. Next, the cage is distanced from the site (figure 3, step 7), possibly varying the parameters (field strength, frequency) to vary the dielectrophoretic force, in such a way as to remove the non-specific antibodies and at the same time verify the specificity of any antigen-antibody bonds. The procedure is repeated for all of the sites making up the array (figure 3, step 8).

The test can be monitored exploiting methods that use fluorescence, chemiluminescence, etc. In the

example of the drawing, an antibody population is labelled with a fluorescent marker molecule (figure 3, step 9) detectable with optical sensors that can be stationed externally to the test chamber compassing the test environment L (microscope, TV camera), or integrated into the device, and more particularly into the substrate C beneath the array of electrodes LIJ. In this instance it is the antigen protein immobilized on the electrode that is identified by means of the labelled antibody.

An alternative option would be to use a method exploiting capacitive sensors integrated into the device (conventional in embodiment and therefore not illustrated), such as will indicate the capacitance associated with the electrode of each single protein site established previously and show the difference in capacitance when another protein binds to those already present at the site (figure 3, step 9). Utilizing this system, the protein to be identified can be either the protein bound to the surface of the electrodes LIJ or the protein soluble in the liquid or semi-liquid environment L, whether antigen or antibody. To this end, the dielectric characteristics of the proteins that serve to bring about recognition, be they antigen



or antibody, can be modified by immobilizing them on microsupports, for example microbeads of a synthetic material that might have known physical characteristics (colour, fluorescence, etc.), in addition to their particular dielectric constant, such as will facilitate recognition internally of the device. In this instance the method according to the invention will also include a step of recognizing the microbeads, conducted according to the nature of these physical characteristics.

The variation in capacitance can be identified employing the methods and circuits disclosed in patent application PCT/WO 00/69565.

One variation on the method according to the present invention relates to a test procedure in which the sample containing the proteins to be identified is immobilized in spatially uniform manner on the surface of the device, above the electrodes, as indicated schematically in figure 4. In this version of the method, a biological sample (serum) containing an unknown heterogeneous antibody population (figure 4, step a) is introduced into the device. The antibodies bind to the electrodes, which can be passivated and/or suitably functionalized (figure 4, step b). Any excess

of unbound antibodies is removed by flushing buffer solution through the chamber of the device (figure 4, step c). Probe microbeads are then introduced into the device, each coated with a known protein that could  
5 bind one of the antibodies. The microbeads are manipulated dielectrophoretically and brought directly into contact with the antibodies covering the electrodes. Alternatively, contact with the antibodies can be brought about by manipulating the microbeads  
10 onto the vertical axes of the electrodes, likewise dielectrophoretically, then deactivating the cages (gravitational method). Binding activity is verified by seeking to raise the dielectrophoretic cage or, alternatively, simply reactivating it in the event that  
15 the microbead was deposited gravitationally. The sensing procedure consists in measuring the difference in capacitance between the electrode and the bead in contact with it or raised in the cage, or moving the cage further, between the electrode with a bead bound  
20 and another one with no beads bound. The presence of a suspected antibody and, if envisaged, an estimate of its concentration, is verified by assessing the number of microbeads bound.

Figure 5 illustrates another procedure suitable

for running the same test. In this instance there is no need for movement of the cages and therefore the method can be implemented using a less complex device, in which the additional circuitry consists in nothing more  
5 than the capacitive sensing circuit. This version of the method disclosed exploits the change in dielectrophoretic force from negative (nDEP) to positive (pDEP). In step a) of figure 5, the microbead, functionalized with protein, is trapped at a given  
10 frequency  $f_1$  in a potential cage above the electrodes (negative dielectrophoresis). Changing to frequency  $f_2$  and increasing the field strength (pDEP) the bead is repelled by the cage and attracted toward a maximum potential, i.e. onto the electrodes, where it enters  
15 into contact with the immobilized antibodies (figure 5, step b).

The antibody-protein binding check is run simply by resetting the frequency to  $f_1$ ; if binding has occurred, the microbead will not be able to return  
20 inside the cage (figure 5, step c1), whereas if binding has not occurred, the cage will again be able to attract the microbead (figure 5, step c2).

Clearly, the microsupport selected for immobilization of the biological entities to be

manipulated and/or identified can be a medium other than a microbead; for example, the molecules of interest might be immobilized on the surfaces of cells or liposomes.

5 In accordance with a further variation on the method, moreover, the antigen-antibody binding force check can be run without using dielectrophoresis, but simply introducing a flow of buffer solution into the environment L, directed through the surrounding  
10 chamber; in this instance it will be hydrodynamic force that induces the bound biological entities to separate from the surface afforded by the electrodes LIJ.

To enable the detection of fluorescent marker molecules, whether associated directly with the  
15 biological entities or with microbeads (or with other microsupports as mentioned above), the device of figure 1 is exposed to electromagnetic radiation at a first predetermined wavelength, for example ultraviolet UV (figure 2) falling directly on the samples BIO  
20 occupying the environment L compassed by the chamber. The elements labelled with fluorescent molecules are selected in such a way, accordingly, as to emit electromagnetic radiation at a second predetermined wavelength different to the first, for example in the

visible spectrum; this radiation can be detected advantageously by sensors integrated into the silicon substrate C. By way of example, figure 6 shows the spectral response for emission from certain typical  
5 fluorescent molecules excited with a monochrome laser emitting ultraviolet radiation at 405 nm.

In accordance with the state of the art, the typical excitation wavelengths for these molecules range from 350 to 480 nm for Ar, Xe-F and Xe ion  
10 lasers. It is therefore important that the optical sensors incorporated into the substrate C should be selective, in particular, not liable to react to ultraviolet radiation, and especially sensitive to radiation in the visible spectrum. This performance  
15 potential can be delivered by employing suitable techniques for the embodiment of semiconductor type optical sensors, which also constitute subject matter of the present invention, as will now be explained.

In general, a photon related to the high flux LIG  
20 (figures 2 and 7) penetrates the substrate C of a semiconductor to the point at which, interacting with a crystal lattice, it pushes an electron from the valence band to the conduction band, in other words generating an electron-hole pair. The probability with which this

phenomenon occurs depends on the average depth to which the photon penetrates the substrate and is directly proportional to its energy. The energy of the photon is  $E = h c / \lambda$  (where  $h$  = Planck constant,  $c$  = speed of light), hence a function of wavelength  $\lambda$ , and therefore the probability of generation is closely related to this latter quantity. Generally considered, experimental data obtainable on silicon substrates show a high generation probability for wavelengths of the order of 200-300 nm, which reduces markedly and exponentially at wavelengths of 800-1000 nm. This phenomenon translates into the fact that photon flux is characterized by a mean penetration length into the silicon dependent on wavelength: a few tens of micrometres (millionths of one metre) for emissions in the ultraviolet range, and several micrometres for those in the infrared range.

One method commonly utilized to quantify photogenerated charges, and thus measure the intensity of the photon stream, consists in establishing a reverse biased p-n junction (XJ or XJW) in the region through which the flux is directed. A device embodied in this fashion is known as a photodiode, denoted CPH in figure 2. The charges generated by light in the

space-charge region W are drawn to the boundaries of this same region by the strong electric field and are quantifiable: 1) by measuring the current they generate, having biased the junction at constant  
5 voltage; 2) by measuring the total charge accumulated at the end of a set time during which the photodiode is not biased (storage-mode technique).

Utilizing planar technology, the foregoing operations are implemented according to the present  
10 invention by placing a contact CON on the diffusion surface of the photodiode CPH, such as can be connected electrically by way of an electronic address switch SW to the input of an electronic charge amplifier CHA. The output OUT of the charge amplifier encodes the amount  
15 of charge and therefore the luminous intensity incident on the photodiode CPH. It is possible to demonstrate that the space-charge region is the main factor responsible for photogeneration current.

The response of the photodiode as a function of  
20 the wavelength of the incident radiation thus depends to a considerable extent on the depth DEP of the junction (figure 7): on the one hand, radiation of short wavelength (ultraviolet) is absorbed in the immediate neighbourhood of the surface, in this

instance not penetrating the space-charge region W, whereas on the other, radiation of relatively long wavelength and bordering on the visible (infrared) will penetrate further into the space-charge region, though  
5 with less likelihood of photogeneration occurring. By reason of these two opposite types of behaviour, peak sensitivity of the photodiode will be localized in the region of the visible, with minimal sensitivity registering at wavelengths in the infrared and  
10 ultraviolet range. Thus, the photodiode embodied in accordance with the present invention has a sensitivity to different types of radiation as characterized by the humped curves of figure 8, with peak sensitivity tending to register at wavelengths in the infrared  
15 spectrum for deeper junctions.

Current MOS planar technology affords different possibilities for the manufacture of photodiodes: in particular, the preferred solution consists in diffusion using shallow-junctions and well-junctions.  
20 Figure 7 illustrates a cross section through a planar MOS device at a well diffusion. More exactly, the drawing shows shallow junctions XJ and well junctions XJW. Figure 8 shows the spectral responses of the two junctions, calculated mathematically on the basis of



the semiconductor device equations, interpolated with experimental absorption data relative to silicon, for a typical CMOS photodiode with detail definition of 0.7  $\mu\text{m}$ . The depths DEP of the two junctions are 0.28  $\mu\text{m}$  for the shallow (XJ) and 2.7  $\mu\text{m}$  for the well (XJW). In accordance with what has already been stated, the spectral response of the deeper junctions, notably the well, indicates a marked sensitivity to infrared radiation and minimal sensitivity to ultraviolet.

10 In conclusion, the use of a deep well junction is particularly suitable for the proposed application, in order to eliminate the influence of ultraviolet radiation while maintaining good sensitivity at visible wavelengths.

15 Another way of increasing the selectivity of the sensors or more simply ensuring a higher level of confidence when using surface junctions (such as those deriving from the most sophisticated technologies), obtainable following procedures already familiar in the art field of semiconductor device manufacture, is that of utilizing suitable colour filters GEL deposited on the surface of the substrate C. These filters can be overlaid on the chip by means of photolithography and consist in colour photoresists or gels characterized by

deposition resolutions of a few tenths of one micrometre ( $\mu\text{m}$ ). In the example of the present disclosure, any ultraviolet interference can be reduced by using filters, tuned in the yellow or green colour range.

In one possible embodiment of optical sensing means according to the invention, the p-n junction XJ or XJW is located in the silicon region C beneath the electrode LIJ, the electrode being fashioned photolithographically from materials that are electrically conductive, but transparent, typically Indium Tin Oxide (ITO). This solution can be obtained by post-processing an integrated circuit produced using the standard silicon technology applied routinely in microelectronics manufacturing processes, whereby the final passivation layer is applied in such a way as to leave portions of the metallization raised and exposed. The metallization is then used to establish an electrical contact between the transparent electrode and the circuits beneath.

In other solutions, utilizing an electrode LIJ of conventional embodiment that may not be transparent to light radiation, the photodiode could be located in the substrate, occupying the gap between the single

electrodes, and the signals selected in such a way as to position the potential cage exactly in the space above the gap. In a further possible solution, electrodes embodied in non-transparent material could  
5 be fashioned with a central window, as mentioned previously, through which light can be directed so as to fall on the substrate beneath incorporating a photodiode.

Lastly, another way of preventing radiation  
10 emitted at the first frequency (UV in the example illustrated) from falling on the photodiode, is to create a waveguide utilizing the oxide of the chip and the glass of the lid, which will allow the fluorophores in the sample to be excited by radiation at a first  
15 frequency, directed laterally into the chamber holding the sample. The waveguide created in this manner will prevent the excitation energy from penetrating the substrate, since the unwanted radiation is reflected from the surface of the array by reason of its minimal  
20 angle of incidence, whilst that emitted by the fluorophores at given points of the array, being omnidirectional, will penetrate the surface of the array.

## CLAIMS

1. A method of conducting integrated biomolecular analyses on a biological sample including unknown biological entities, with the aid of known biological entities capable of binding to the unknown biological entities, comprising the steps of immobilizing first biological entities directly or indirectly on a support, bringing second biological entities into contact with said first biological entities and detecting any binding activity between at least a proportion of said first biological entities and at least a proportion of said second biological entities; said first or said second biological entities being said unknown entities and said second or said first biological entities being said known entities; characterized:

(A)- in that said support is provided by a surface consisting in an array of first electrodes (LIJ) selectively energizable and addressable at least in part, disposed facing and distanced by means of a spacer from at least one second electrode (M2), in such a manner that said second electrode, said spacer and said array of first electrodes (LIJ) combine to establish a test chamber such as will compass a liquid

or semi-liquid environment (L) in which closed dielectrophoretic cages (S1) are generated selectively by means of said first electrodes (LIJ) and said second electrode (M2) for the purpose of trapping and moving  
5 at least said second biological entities in said chamber;

(B) - in that said surface is treated beforehand in such a way as to promote binding with said first biological entities at said first electrodes (MIJ).

10 2. A method as in claim 1, wherein the immobilizing step comprises the single steps of:

a. introducing a suspension of said first biological entities into said chamber compassing said liquid or semi-liquid environment (L);

15 b. trapping and levitating said first biological entities within dielectrophoretic potential cages (S1, DEP) generated between selected first electrodes (LIJ) and said second electrode (M2);

c. selectively directing said dielectrophoretic cages  
20 (S1), with said first biological entities trapped within them, toward selected first electrodes (MIJ);

d. moving said cages (S1) in such a way as to bring about said binding between said first biological entities and said selected first electrodes (MIJ) and

consequently immobilizing said first biological entities on said electrodes, according to a predetermined patterning sequence.

3. A method as in claim 2, further comprising the  
5 step of concentrating said first biological entities at selected first electrodes (MIJ) by bringing together and fusing two or more said dielectrophoretic cages (S1) containing one or more said first biological entities trapped within them.

10 4. A method as in any one preceding claim, wherein said first biological entities are said known biological entities, and said second biological entities are said unknown biological entities, further comprising the steps of:

15 e. introducing a suspension of populations of second biological entities, conceivably of two or more different types, into said chamber;

f. concentrating at least one first part of the population of said second biological entities by  
20 attracting them into a dielectrophoretic cage (S1) generated between said electrodes (LIJ,M2);

g. moving said at least one first part of the population of said second biological entities and causing it to interact with at least part of a

population of said known first biological entities immobilized on said surface at a selected first electrode (LIJ);

h. sensing any binding activity between at least one  
5 part of the population of unknown second biological entities and at least one part of the population of said known first biological entities immobilized on the first electrodes (LIJ).

5. A method as in claim 4, wherein said binding  
10 activity is verified by seeking to separate said populations of first and/or second biological entities one from another and/or from said first electrodes dielectrophoretically, trapping them within dielectrophoretic cages (S1) and distancing the cages  
15 from selected first electrodes (LIJ).

6. A method as in claim 4 or 5, wherein said binding activity is sensed by means of optical type sensors either located externally of said chamber or integrated into said array of first electrodes (LIJ).

20 7. A method as in claim 4 or 5, wherein said binding activity is sensed by means of capacitive type sensors.

8. A method as in claim 6 or 7, comprising a step of immobilizing said unknown second biological entities on microbeads having predetermined physical and chemical

characteristics, such as will increase the capacitive or optical detectability of said binding activity.

9. A method as in claim 6, wherein use is made of optical sensors integrated into said array of first electrodes (LIJ), comprising the steps of: treating  
5 said second biological entities that will be bound to said first biological entities immobilized on the first electrodes (LIJ), with a substrate including fluorophore groups; exciting said fluorophores  
10 associated with the unknown first biological entities by exposing them to light emitted at a first wavelength (UV); sensing the emission of fluorescence at a second wavelength (LIG) different to the first by means of said integrated optical sensors in such a way as to  
15 determine the presence of the second biological entities bound to the first in close proximity to each first electrode (LIJ).

10. A method as in claims 1 to 3, wherein said first biological entities are said unknown biological  
20 entities, and said second biological entities are said known biological entities, further comprising the steps of:

i. immobilizing populations of second biological entities, conceivably of two or more different types,



on microsupports having predetermined physical and chemical characteristics, conceivably different one to another;

1. introducing microsupports of at least one first type  
5 carrying said immobilized known second biological entities, into said chamber, and trapping them in dielectrophoretic cages (S1);

m. causing said microsupports trapped in said dielectrophoretic cages (S1) to interact with said  
10 surface consisting in said array of first electrodes (LIJ) occupied by immobilized populations of said unknown first biological entities conceivably different one from another;

n. verifying the force of any binding that occurs by  
15 seeking to separate said microsupports from said surface dielectrophoretically, trapping the microsupports within dielectrophoretic cages (S1) and distancing the cages from selected first electrodes (LIJ);

20 p. sensing a possible presence of the microsupports where binding occurs with said selected first electrodes (LIJ) to determine whether or not said binding is still occurring.

11. A method as in claim 10, wherein said

microsupports are selected from a group including microbeads of synthetic material, cells and liposomes.

12. A method as in claim 11, wherein the microsupports are microbeads of at least two types distinguishable  
5 one from another on the basis of one or more physical parameters including dielectric constant, colour, transparency or fluorescence, further comprising the step of identifying the microsupport before implementing steps (n) and (p).

10 13. A method as in claims 10 to 12, wherein the step of causing interaction (m) is effected by shifting the dielectrophoretic cages (S1) toward the surface.

14. A method as in claims 10 a 12, wherein the step of causing interaction (m) is effected by eliminating the  
15 dielectrophoretic cages (S1) and causing the microsupports to precipitate onto the surface.

15. A method as in claims 10 to 12, wherein the step of causing interaction (m) is effected by changing the excitation frequency of said electrodes (LIJ) so as to  
20 generate a positive dielectrophoretic force (pDEP) such as will repel the microsupports from the respective dielectrophoretic cages (S1) and thus direct them into contact with the surface.

16. A method as in claims 10 to 13, wherein the step

of verifying binding force (n) dielectrophoretically is effected by distancing the dielectrophoretic cages from the surface.

17. A method as in claim 14, wherein the step of  
5 verifying binding force (n) dielectrophoretically is effected by reactivating the dielectrophoretic cages (S1) to raise the microsupports from the surface.

18. A method as in claim 15, wherein the step of  
10 verifying binding force (n) dielectrophoretically is effected by restoring the initial excitation frequency so as to attract the microsupports toward the dielectrophoretic cages (S1).

19. A method as in claims 10 to 15, wherein the step  
15 of verifying binding force (n) dielectrophoretically is replaced with a verification step (n') effected by exposing the microsupports to a flow of buffer solution directed through said chamber.

20. A method as in claims 10 a 19, wherein the step of  
20 sensing the presence of the microsupport (p) in the position of a selected electrode (LIJ) is effected utilizing a capacitive sensor associated with the electrode (LIJ).

21. A method as in claims 10 to 19, wherein the step  
of sensing the presence of the microsupport (p) at the

site of a selected electrode (LIJ) is effected utilizing an optical sensor associated with the electrode (LIJ).

22. A method as in claim 21, wherein said optical  
5 sensor detects radiation emitted at a first frequency (LIG) from fluorophore groups associated with said microsupport, excited by radiation emitted at a second frequency (UV) not detectable by said optical sensor.

23. A method as in claim 21, wherein said optical  
10 sensor detects the variation in incident radiation accompanying the absorption or reflection by said microsupport of a measure of radiation originating externally to said test chamber.

24. A method as in claims 10 to 19, wherein the  
15 presence of said microsupport is sensed by an optical sensor located externally to said test chamber.

25. A device for molecular biological analyses performed with the aid of movable dielectrophoretic cages (S1, DEP), comprising a surface afforded by an  
20 array (M1) of first electrodes (LIJ) selectively energizable and addressable at least in part and arranged on an insulating support (O1); at least one second electrode (M2) positioned opposite and facing at least a part of said array (M1) of first electrodes

(LIJ); and a spacer serving to distance the first electrodes (LIJ) from said at least one second electrode (M2) in such a way that said second electrode, said spacer and said array (M1) of first electrodes combine to establish a test chamber encompassing a liquid or semi-liquid environment (L); characterized in that it further comprises integrated optical sensors located beneath or in close proximity to at least one of said first electrodes (LIJ); and in that said first electrodes (LIJ) comprise means by which to allow the transmission of electromagnetic radiation (UV;LIG) through the selfsame first electrodes (LIJ) and toward said optical sensors, operating in conjunction with means likewise forming part of the device and positioned to coincide with said first electrodes (LIJ), by which radiation of a first predetermined wavelength (UV) is prevented from reaching said integrated optical sensors.

26. A device as in claim 25, wherein said means by which to allow the passage of electromagnetic radiation (UV;LIG) toward said optical sensors are one and the same as said first electrodes (LIJ), and embodied in a material transparent to said radiation.

27. A device as in claim 25, wherein said means by

which to allow the passage of electromagnetic radiation (UV;LIG) toward said optical sensors include respective windows transparent to said radiation, incorporated into said first electrodes (LIJ) preferably at the  
5 centre thereof.

28. A device as in any one of claims 25 to 27, wherein said means by which radiation of first predetermined wavelength (UV) is prevented from reaching said integrated optical sensors consist in respective band-  
10 pass filters (GEL) positioned to coincide with said first electrodes (LIJ) on said surface.

29. A device as in claim 28, wherein said band-pass filters (GEL) consist in an overlay of gel applied to said first electrodes (LIJ) and having selective  
15 optical properties such as will attenuate said radiation of first predetermined wavelength (UV).

30. A device as in any one of claims 25 to 27, wherein said means by which radiation of first predetermined wavelength (UV) is prevented from reaching said integrated optical sensors consist in a waveguide  
20 positioned to coincide with said first electrodes (LIJ) and serving to bring about a reflection of said radiation of first predetermined wavelength (UV) from said array (M1) of first electrodes (LIJ).

31. A device as in any one of claims 25 to 29, wherein  
said integrated optical sensors consist in junction  
photodiodes (CPH) located at a given depth (DEP) from a  
surface of a semiconductor substrate (C) such as to  
5 render them substantially insensitive to said radiation  
of first predetermined wavelength (UV).

1 / 5




Fig. 1




Fig. 2

SUBSTITUTE SHEET (RULE 26)



2 / 5




Fig. 3




Fig. 4

3 / 5




Fig. 5




Fig. 6

4 / 5




Fig. 7

5 / 5




Fig. 8

## INTERNATIONAL SEARCH REPORT

PCT/IT 02/00524

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G01N33/543 G01N27/447

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 69565 A (MEDORO GIANNI ; SILICON BIOSYSTEMS S R L (IT)) 23 November 2000 (2000-11-23) cited in the application	25-27, 31
Y	the whole document	1-24, 28-30
Y	EP 1 088 592 A (WAKO PURE CHEM IND LTD) 4 April 2001 (2001-04-04) page 3, line 30-45 page 4, line 9-17 page 6, line 27 -page 7, line 50; examples 1,2 -/-	1-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

8 January 2003

Date of mailing of the international search report

31/01/2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Diez Schlereth, D

## INTERNATIONAL SEARCH REPORT

PCT/IT 02/00524

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHENG J ET AL: "PREPARATION AND HYBRIDIZATION ANALYSIS OF DNA/RNA FROM E. COLI ON MICROFABRICATED BIOELECTRONIC CHIPS" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 16, June 1998 (1998-06), pages 541-546, XP000992691 ISSN: 1087-0156 the whole document	1-24
Y	US 6 197 503 B1 (VO-DINH TUAN ET AL). 6 March 2001 (2001-03-06) column 6, line 1 -column 13, line 50	28-30
A	WO 00 32744 A (NANOGEN INC) 8 June 2000 (2000-06-08) page 9, line 25 -page 18, line 29	1-31
P,X	J. M. YANG ET AL.: "AN INTEGRATED, STACKED MICROLABORATORY FOR BIOLOGICAL AGENT DETECTION WITH DNA AND IMMUNOASAYS" BIOSENSORS & BIOELECTRONICS, vol. 17, 2002 - 26 June 2002 (2002-06-26), pages 605-618, XP002226513 the whole document	1-24

# INTERNATIONAL SEARCH REPORT

PCT/IT 02/00524

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☒ As all searchable claims could be searched without effort justifying an additional fee; this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/IT 02 00524

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

### 1. Claims: 1-31

Method and device for conducting integrated biomolecular analyses

The present application lacks unity within the sense of Rule 13.1 PCT because there is no novel and inventive concept within the sense of Rule 13.2 PCT linking the subject-matter of independent claims 1 and 25.

It would appear that the apparatus of claim 25 is not specially adapted to carry out the method of claim 1. First of all, the method of claim 1 requires a modification of the electrode array surface for promoting binding of a capture binding reagent and this feature is not included in the device of claim 25. Furthermore, it would appear that the subject-matter of claim 25 is already known from the state of the art (see W000/69565).

#### 1.1. Claims: 1-24

method for conducting biomolecular analyses involving carrying out binding reactions in closed dielectrophoretic cages.

#### 1.2. Claims: 25-31

integrated electro-optical device for molecular biological analyses with the aid of movable dielectrophoretic cages.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.



## INTERNATIONAL SEARCH REPORT

PCT/IT 02/00524

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0069565	A	23-11-2000	IT B0990262 A1	20-11-2000
			AU 4601300 A	05-12-2000
			CN 1361720 T	31-07-2002
			EP 1185373 A1	13-03-2002
			WO 0069565 A1	23-11-2000
			US 2002125138 A1	12-09-2002
EP 1088592	A	04-04-2001	EP 1088592 A2	04-04-2001
			JP 2001165905 A	22-06-2001
			JP 2001165906 A	22-06-2001
US 6197503	B1	06-03-2001	AU 1609399 A	15-06-1999
			CA 2311466 A1	03-06-1999
			EP 1236807 A2	04-09-2002
			EP 1034305 A1	13-09-2000
			WO 9927140 A1	03-06-1999
			US 6448064 B1	10-09-2002
WO 0032744	A	08-06-2000	US 6309602 B1	30-10-2001
			US 6375899 B1	23-04-2002
			US 6319472 B1	20-11-2001
			AU 1742300 A	19-06-2000
			WO 0032744 A1	08-06-2000



CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 2003/014739 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/543**,  
27/447

(21) International Application Number:  
PCT/IT2002/000524

(22) International Filing Date: 7 August 2002 (07.08.2002)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
TO01A000801 7 August 2001 (07.08.2001) IT

(71) Applicant (for all designated States except US): **SILICON BIOSYSTEMS S.R.L.** [IT/IT]; Viale Ercolani, 3, I-40138 Bologna (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MANARESÌ, Nicolò** [IT/IT]; Via Santo Stefano, 132, I-40138 Bologna (IT). **MEDORO, Gianni** [IT/IT]; Via Ugo Lamalfa, 3, I-71049 Trinitapoli (IT). **ALTOMARE, Luigi** [IT/IT]; Via Misa,

6, I-40139 Bologna (IT). **TARTAGNI, Marco** [IT/IT]; Via Mastri, 17, I-47014 Meldola (IT). **GUERRIERI, Roberto** [IT/IT]; Via Calari, 19/2, I-40122 Bologna (IT).


(74) Agents: **JORIO, Paolo** et al.; Studio Torta S.r.l., Via Viotti, 9, I-10121 Torino (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]


(54) Title: METHOD AND DEVICE FOR INTEGRATED BIOMOLECULAR ANALYSES




1) antigen routing



2) binding and excess removal



3) repeated patterning




4) introduce sample



5) concentrate



6) bind to site



7) electronic affinity check



8) site scanning



9) sensing

(57) Abstract: A method whereby first biological entities are recognized by way of second biological entities able to bind to the first (or the first to the second), including the steps of binding first biological entities to a surface comprising an array of first electrodes selectively energizable and addressable at least in part, positioned facing at least one second electrode, bringing the second biological entities into contact with the first, these second biological entities and possibly the first being moved by means of dielectrophoretic cages generated between the electrodes, and sensing any binding activity between at least a portion of the first and of the second biological entities, preferably utilizing radiation at a first frequency to excite fluorophore groups bound to the second biological entities and detecting the emission of fluorescence at a second frequency by means of optical sensors integrated into the electrodes, the biological entities preferably being concentrated on the electrodes by the fusion of dielectrophoretic cages.

WO 2003/014739 A1



**Published:**

— *with international search report*

**(48) Date of publication of this corrected version:**

8 April 2004

**(15) Information about Correction:**

see PCT Gazette No. 15/2004 of 8 April 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>G01N 27/26, 27/447, C12N 15/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/10273</b> <b>(43) International Publication Date:</b> 12 March 1998 (12.03.98)
<b>(21) International Application Number:</b> PCT/US97/14489 <b>(22) International Filing Date:</b> 18 August 1997 (18.08.97)  <b>(30) Priority Data:</b> 08/708,262                      6 September 1996 (06.09.96)                      US  <b>(71) Applicant:</b> NANOGEN, INC. [US/US]; 10398 Pacific Center Court, San Diego, CA 92121 (US).  <b>(72) Inventors:</b> SOSNOWSKI, Ronald, George; 1013 Adella Avenue, Coronado, CA 92118 (US). BUTLER, William, Frank; 7577 Caloma Circle, Carlsbad, CA 92009 (US). TU, Eugene; 3527 Lark Street, San Diego, CA 92103 (US). NERENBERG, Michael, Irving; 11256 Caminito Inocenta, San Diego, CA 92126 (US). HELLER, Michael, James; 1614 Hawk View Drive, Encinitas, CA 92024 (US).  <b>(74) Agents:</b> MURPHY, David, B. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		<b>(81) Designated States:</b> AU, BR, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS AND MATERIALS FOR OPTIMIZATION OF ELECTRONIC HYBRIDIZATION REACTIONS		
<b>(57) Abstract</b>  The following inventions relate to discoveries concerning the various parameters, electrolytes (buffers), and other conditions which improve or optimize the speed of DNA transport, the efficiency of DNA hybridization reactions, and the overall hybridization specificity in microelectronic chips and devices. In particular, this invention relates to the discovery that low conductance zwitterionic buffer solutions, especially those containing the amino acid Histidine prepared at concentrations of ~50 mM and at or near the pI (isoelectric point ~pH 7.47), provide optimal conditions for both rapid electrophoretic DNA transport and efficient hybridization reactions. Hybridization efficiencies of at least a factor of 10 relative to the next best known buffer, Cysteine, are achieved. Test data demonstrate an approximately 50,000 fold increase in hybridization efficiency compared to Cysteine.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTIONMethods And Materials For Optimization  
Of Electronic Hybridization ReactionsField of the Invention

This invention relates to buffers and electrolytes for use in electronic devices adapted for medical diagnostic, biological and other uses. More particularly, it relates to buffers and electrolytes for advantageous use with DNA hybridization analysis carried out on microelectronic medical diagnostic devices.

Background of the Invention

Recently, there has been increasing interest in devices which combine microelectronics and molecular biology. One such system is disclosed in "ACTIVE PROGRAMMABLE ELECTRONIC DEVICES FOR MOLECULAR BIOLOGICAL ANALYSIS AND DIAGNOSTICS", Serial No. 08/146,504, filed November 1, 1993, now issued as United States Patent No. 5,605,662, incorporated herein by reference. The systems disclosed therein will be referred to as APEX systems. APEX systems are able to perform a wide variety of functions which are advantageously used in molecular biology reactions, such as nucleic acid hybridizations, antibody/antigen reactions, clinical diagnostics, and biopolymer synthesis.

APEX-type devices utilize buffers and electrolytes for their operation. A buffer has been defined as a chemical solution which is resistant to change in pH on the addition of acid or alkali. See., e.g., Dictionary of Biotechnology, Second Edition, James Coombs, Stockton Press. As stated there, "traditionally, buffers based on inorganic salts (phosphate, carbonate) and organic acid salts (acetate, citrate, succinate, glycine, maleate, barbiturates, etc.) were used in biological experiments."

It is the object of this invention to discover buffers and electrolytes which are advantageously used in molecular biology electronic devices which perform hybridizations, reactions, diagnostics or synthesis.

#### 5 Summary of the Invention

The following inventions relate to our discoveries concerning the various parameters, electrolytes (buffers), and other conditions which improve or optimize the speed of DNA transport, the efficiency of DNA hybridization  
10 reactions, and the overall hybridization specificity in our APEX microelectronic chips and devices. In particular, this invention relates to the discovery that low conductance zwitterionic buffer solutions, especially those containing the amino acid Histidine prepared at  
15 concentrations of 10-100 mM, preferably about 50 mM, and at or near the pI (isoelectric point ~pH 7.47), provide optimal conditions for both rapid DNA transport and efficient hybridization reactions. Hybridization efficiencies of at least a factor of 10 relative to the  
20 next best known buffer, Cysteine, are achieved. Test data demonstrate an approximately 50,000 fold increase in hybridization efficiency compared to Cysteine.

#### Brief Description of the Drawings

Fig. 1 is a plan view of a checkerboard arrangement  
25 utilizing a histidine buffer.

#### Detailed Description of the Invention

There are various physical parameters which relate to the electrophoretic transport of DNA and other charged analytes in various types of electrolyte/buffer solutions.  
30 Certain of the devices, e.g., Applicant's APEX device as described in United States Patent No. 5,605,662, referenced above, are basically DC (direct current) electrical devices which generate electric fields on the surface of the device. These fields, in turn, cause the



electrophoretic transport of charged molecules to occur between oppositely (+/-) biased microlocations on the device surface. By contrast the so-called Genosensor (impedance sensors), see, e.g., Hollis et al, "Optical and  
5 Electrical Methods and Apparatus for Molecular Detection", WO93/22678, and dielectrophoresis devices, see, e.g., Washizu 25 Journal of Electrostatics, 109-123, 1990, involve the use of AC electric fields. An important distinction related to these devices is that when these AC  
10 fields are applied, there is essentially no net current flow in any of these systems, i.e, there is no electrophoretic propulsion for transport of the charged molecules. APEX type devices produce significant net direct current (DC) flow when a voltage is applied, which is recognized  
15 as "the signature of electrophoresis". In electrophoresis, the migration of ions or charged particles is produced by electrical forces along the direction of the electric field gradient, and the relationship of current and voltage are important to this technology. The  
20 electrophoretic migration shows itself macroscopically as the conduction of electric current in a solution under the influence of an applied voltage and follows Ohm's law:

$$V=RxI$$

V is the electric potential

25 R is the electric resistance of the electrolyte [ $V \times A^{-1} = R(\Omega)$ ]

I is the electric current [A].

The resistance of the solution is the reciprocal of the conductance which can be measured by a conductometer.  
30 The conductance depends mainly on the ionic species of the buffer/electrolytes and their concentration; therefore these parameters are very important for electric field related molecular biology technology. The basic current/voltage relationships are essentially the same for  
35 the APEX technology as for any other electrophoretic system, although the electric fields produced are in truly microscopic environments.

There are unique features of the APEX system regarding the various ways of sourcing the current and voltage, and how the current and voltage scenarios have been found to improve the performance of such systems. In particular, various DC pulsing procedures (linear and logarithmic gradients) appear to provide improved hybridization stringency.

#### Electrophoretic Transport Versus Ionic Strength

It is well established in the field of electrophoresis that there is a logarithmic decrease in the mobility of the charged analyte species (proteins, DNA, etc.), which is inversely proportional to the square root of the ionic strength of the electrolyte solution (see page 83 and Fig. 3.16 in "Capillary Electrophoresis: Principles and Practice", R. Kuhn and S. Hoffstetter, Springer-Verlag, 1993). At any given constant electric field strength, as the electrolyte concentration decreases relative to the analyte species (protein, DNA, etc.), the analyte will be transported at a faster rate. Similar results demonstrating this effect for a danylated amino acid have been shown by J.J. Issaq et. al., Chromatographia Vol. 32, #3/4, August 1991, pages 155 to 161 (see in particular Fig. 3 on page 157). Results demonstrating this effect for DNA in different electrolyte solutions has been shown in P.D. Ross and R.L. Scruggs, Biopolymers Vol. 2, pages 231 to 236, 1964 (see in particular Fig. 1, page 232).

#### Ionic Strength/Conductance Relationship

For those non-buffering electrolytes (sodium chloride, potassium chloride, etc.) which involve completely dissociated anion and cation species in solution ( $\text{Na}^+ \longleftrightarrow \text{Cl}^-$ ,  $\text{K}^+ \longleftrightarrow \text{Cl}^-$ , etc.), the ionic strength and conductance are equivalent, i.e., the conductance will usually be proportional to the ionic strength. For those buffering electrolytes (phosphate,

acetate, citrate, succinate, etc.) which are in their dissociated states (example:  $2 \text{Na}^+ \rightleftharpoons \text{PO}_4^{--2}$ ), the ionic strength and conductance will usually be equivalent, i.e., conductance is proportional to the ionic strength. For those buffering electrolytes [Good Buffers (MOPS, HEPES, TAPS, Tricine, Bicine), Amino Acid Buffers, Ampholytes, etc.] which can have a zwitterionic species (no net charge at their  $pI$ ), the conductance will decrease by approximately a factor of 10 for every pH unit difference between the isoelectric point ( $pI$ ) and the ( $pK_a$ ). For example, an amino acid in its zwitterionic state ( $^-\text{OOC}-\text{CH}(\text{R})-\text{NH}_3^+$ ) will have a conductance value which will be approximately 1000 fold lower than when the "amino acid moiety" has a full net positive charge ( $\text{HOOC}-\text{CH}(\text{R})-\text{NH}_3^+ \rightleftharpoons \text{X}^+$ ), or a full negative charge ( $\text{Y}^- \rightleftharpoons ^-\text{OOC}-\text{CH}(\text{R})-\text{NH}_2$ ). Thus, a formal negative or positive charge develops on the amino acid moiety as it moves away from its  $pI$ , and the conductivity and ionic strength will begin to correlate. However, when at or near the  $pI$  the conductance will be much lower than is expected for that given ionic strength or concentration. When used at or near their  $pI$ 's, electrophoresis texts refer to the Good Buffers and amino acid buffers as having "low conductances at high ionic strength or concentration" (see page 88 of Capillary Electrophoresis: Principles and Practice", R. Kuhn and S. Hoffstetter, Springer - Verlag, 1993). A commonly used electrophoresis buffer "Tris-Borate" actually has a significantly lower conductivity than would be expected from its ionic strength or concentration. This may be due to the "tris cation" and "borate anion" forming a relatively stable zwitterionic complex in solution. The conductivity of a 100 mM Tris-Borate solution was determined to be 694  $\mu\text{S}/\text{cm}$ , which is approximately 20 times lower than would be expected from its ionic strength, and is roughly equivalent to a 5 mM sodium phosphate or sodium chloride solution. Table 1 shows conductivity measurements of a number of transport buffers.

	Solution/B uffer	Measurement 1	Measurement 2	Measurement 3	Average/Std. Deviation
	10 mM MgCl <sub>2</sub>	1.95 mS/cm	2.02 mS/cm	2.13 mS/cm	2.03+/-0.09 mS/cm
5	1 mM MgCl <sub>2</sub>	174 $\mu$ S/cm	208 $\mu$ S/cm	177 $\mu$ S/cm	186+/-18.8 $\mu$ S/cm
	0.1 mM MgCl <sub>2</sub>	16.9 $\mu$ S/cm	16.7 $\mu$ S/cm	18.3 $\mu$ S/cm	17.3+/-0.87 $\mu$ S/cm
	10 mM NaCl	1.07 mS/cm	1.10 mS/cm	1.18 mS/cm	1.12+/-0.057 mS/cm
	1 mM NaCl	112 $\mu$ S/cm	115 $\mu$ S/cm	111 $\mu$ S/cm	112.7+/-2.08 $\mu$ S/cm
10	0.1 mM NaCl	8.80 $\mu$ S/cm	8.98 $\mu$ S/cm	10.5 $\mu$ S/cm	9.43+/-0.93 $\mu$ S/cm
	20 mM NaPO <sub>4</sub>	2.90 mS/cm	2.79 mS/cm	3.00 mS/cm	2.90+/-0.11 mS/cm
15	10 mM NaPO <sub>4</sub>	1.40 mS/cm	1.44 mS/cm	1.48 mS/cm	1.44+/-0.04 mS/cm
	1 mM NaPO <sub>4</sub>	122 $\mu$ S/cm	128 $\mu$ S/cm	136 $\mu$ S/cm	128.7+/-7.0 $\mu$ S/cm
	50 mM TRIS	3.50 mS/cm	3.14 mS/cm	3.40 mS/cm	3.35+/-0.19 mS/cm
	10 mM TRIS	572 $\mu$ S/cm	562 $\mu$ S/cm	583 $\mu$ S/cm	572+/-10.5 $\mu$ S/cm
20	250 mM HEPES	141 $\mu$ S/cm	144 $\mu$ S/cm	158 $\mu$ S/cm	147.6+/-9.07 $\mu$ S/cm
	25 mM HEPES	9.16 $\mu$ S/cm	9.44 $\mu$ S/cm	10.5 $\mu$ S/cm	9.7+/-0.71 $\mu$ S/cm
	3.3 mM NaCitrate	964 $\mu$ S/cm	964 $\mu$ S/cm	1.03 mS/cm	986+/-38.1 $\mu$ S/cm
25	5 mM NaSuccinate	1.05 mS/cm	960 $\mu$ S/cm	1.01 mS/cm	1.01+/-0.045 mS/cm
	5 mM NaOxalate	1.02 mS/cm	1.03 mS/cm	1.12 mS/cm	1.06+/-0.055 mS/cm
30	10 mM NaAcetate	901 $\mu$ S/cm	917 $\mu$ S/cm	983 $\mu$ S/cm	934+/-43.5 $\mu$ S/cm
	250 mM Cysteine	27.4 $\mu$ S/cm	17.3 $\mu$ S/cm	23.5 $\mu$ S/cm	22.7+/-5.09 $\mu$ S/cm
35	Milli-Q water	<0.5 $\mu$ S/cm			Detection limit of
					0.1 cell too low

Table 1

Zwitterionic Buffers/Conductance/Transport Rate

Certain advantages exist regarding the rate or speed of electrophoretic transport of DNA when using Zwitterionic buffers (Good buffers, amino acid buffers), or the Tris-Borate buffer at or near their pIs. These are: 1) such buffers can be used at relatively high concentrations to increase buffering capacity, 2) their conductances are significantly lower than other types of buffers at the same concentration, and 3) one gains the advantage of higher electrophoretic transport rates for the analyte of interest (DNA).

Zwitterionic Buffer Capacity at the Isoelectric Point (pI)

Amino acid buffers do have buffer properties at their pI's. While a given amino acid may or may not have its "highest buffering capacity" at its pI, it will have some degree of buffering capacity. Buffer capacity decreases by a factor of 10 for every pH unit difference between the pI and the pKa; those amino acids with three ionizable groups (histidine, cysteine, lysine, glutamic acid, aspartic acid, etc.) generally have higher buffering capacities at their pI's than those amino acids with only two dissociations (glycine, alanine, leucine, etc.). For example, histidine pI = 7.47, lysine pI=9.74, and glutamic acid pI=3.22, all have relatively good buffering capacity at their pIs, relative to alanine or glycine which have relatively low buffering capacities at their pIs (see A.L. Lehninger, Biochemistry, 2ed, Worth Publishers, New York, 1975; in particular Fig. 4-8 on page 79, and Fig. 4-9 on page 80). Histidine has been proposed as a buffer for use in gel electrophoresis, see, e.g., U.S. Patent 4,936,963; but hybridization is not performed in such systems. Cysteine is in a more intermediate position, with regard to buffering capacity. The pI of cysteine is 5.02, the pKa for the  $\alpha$  carboxyl group is 1.71, the pKa for the sulfhydryl is 8.33, and the pKa for  $\alpha$  amino group is 10.78. An acid /base titration curve of 250 mM cysteine,

shows that cysteine has a better "buffering capacity" at ~ pH 5 than a 20 mM sodium phosphate. In the pH 4 to 6 range, the buffering capacity of cysteine is significantly better than 20 mM sodium phosphate, particularly at the higher pH. However, in these pH ranges the conductance of the 250 mM cysteine solution is very low ~23  $\mu$ S/cm, compared to 20 mM sodium phosphate which has a value of ~2.9 mS/cm, a factor of 100 times greater. Figure 1 shows the Conductivity Measurements of Various Transport Buffers.

Several electrophoretic techniques developed over 20 years ago are based on the ability to separate proteins in zwitterionic buffers "at their pIs." These techniques are called Isoelectrophoresis, Isotachophoresis, and Electrofocusing (see chapters 3 and 4 in "Gel Electrophoresis of Proteins: A Practical Approach" Edited by B.D. Hames & D. Rickwood, IRL Press 1981). Various amino acid buffers and Good buffers were used for these applications, all at their pI's (see Table 2, page 168 of the above reference).

#### DNA Transport in Low Ionic Strength and Low Conductance Buffers

A series of fluorescent checkerboard experiments were carried out using 2.5% agarose coated 5580 chips and the ByTr-RCA5 fluorescent probe. We were able to achieve rapid (6 second) checkerboard addressing in all of the following systems: (1) 250 mM HEPES (low conductance), (2) 10  $\mu$ M sodium succinate, (3) 10  $\mu$ M sodium citrate, and (4) distilled water. The results for sodium citrate are shown in Figure 1. While, some types of low conductance or low ionic strength solutions may have somewhat better characteristics, checkerboard addressing and rapid DNA transport (6 to 12 second DNA accumulation on an 80  $\mu$ m pad) were achieved using all of these systems. Additionally, DNA addressing APEX chips in distilled water is possible because the DNA (itself a polyanion) is the

electrolyte present in the bulk solution which provides the conductance. Fig. 1 shows a plan view of an APEX chip using histidine.

5 Relationship of Electrophoretic Transport Rate and the Cation/Anion Species

In addition to the fact that the mobility of the charged analyte species (DNA, proteins, etc.) is related to the ionic strength of the electrolyte solution, the mobility is also greatly influenced by the nature of the cation and anion species in the electrolyte solution (see 10 pp 89 of "Capillary Electrophoresis: Principles and Practice" reference). This particular point is demonstrated for DNA transport in the above Biopolymers, Vol. 2, pp. 231-236, 1964 reference. Figure 1 on page 232 15 of this reference shows the change in DNA mobility when using electrolytes with different univalent anions ( $\text{Li}^+ > \text{Na}^+ > \text{K}^+ > \text{TMA}^+$ ) at the same ionic strength. Basically, different cations can have different association constants with the DNA phosphate groups, and/or change the hydration 20 spheres around the DNA molecules, which leads to a change in their transport rate.

The instant invention relates to our discoveries concerning the various parameters, electrolytes (buffers), and other conditions which improve or optimize the speed 25 of DNA transport, the efficiency of DNA hybridization reactions, and the overall hybridization specificity in electric field molecular biology devices, especially APEX microelectronic chips and devices. In particular, this invention relates to our discovery that low conductance 30 zwitterionic buffer solutions containing the amino acid Histidine prepared at concentrations of 10-100 mM, especially about 50 mM, at or near the pI (isoelectric point ~7.47), provide optimal conditions for both rapid electrophoretic DNA transport and efficient hybridization 35 reactions. This advantage of the Histidine buffer is particularly important for the APEX chip type devices.

These particular devices (as opposed to the micromachined type devices) have limitations as to the amount of current and voltages that can be applied. This limitation makes it difficult to achieve both rapid transport and efficient hybridization using the same buffer system. In these cases, DNA transport was carried out in a low conductance buffer (Cysteine or Alanine) where the limited current/voltage still produced rapid transport. Under these conditions the DNA accumulated at the test site, but did not hybridize as efficiently. After transport in these low conductance buffers, the solution was changed to a high salt buffer (> 100 mM sodium chloride or sodium phosphate) which then produced an efficient hybridization at the test site.

Table 2 shows the results for a series of experiments which correlate the parameters of buffer capacity, pH, and the conductivity, with DNA accumulation and hybridization sensitivity (efficiency) using the APEX chip device.



Solution	Buffer Capacity pH 4-10		pH at PI	Conduc- tivity ( $\mu$ S)	Relative DNA Transport Rate	SA- Biotin T12 Sensi- tivity	Hybridiza- tion Sensitiv- ity of DNA
$\beta$ -Alanine	pK <sub>1</sub> - 3.6 pK <sub>2</sub> - 10.2	+	7.3	10.0	+++++ (fastest)	$3 \times 10^6$	
Taurine	pK <sub>1</sub> - 1.5 pK <sub>2</sub> - 8.7	+/-	4.6	4.5	++++	$> 7.5 \times 10^{10}$	
Cysteine	pK <sub>1</sub> - 1.7 pK <sub>2</sub> - 8.3 pK <sub>3</sub> - 10.8	+/-	5.2	25.0	++++	$3 \times 10^7$	$7.5 \times 10^{10}$
Histidine	pK <sub>1</sub> - 1.8 pK <sub>2</sub> - 6.0 pK <sub>3</sub> - 9.0	+++	7.6	212.0 (172.0 hi purity)	+++	$3 \times 10^6$	$3 \times 10^6$
Lysine	pK <sub>1</sub> - 2.2 pK <sub>2</sub> - 8.9 pK <sub>3</sub> - 10.3	++	9.6	477.0	++	$> 7.5 \times 10^{10}$	
NaPO <sub>4</sub>	Complex	+	7.4 <sup>1/</sup>	1,400.0	+ (slowest)		

TABLE 2

In particular, Table 2 shows the effect of various zwitterionic amino acid buffers [ $\beta$ -Alanine, Taurine, Cysteine, Histidine, Lysine, and Sodium Phosphate (not a zwitterionic buffer)] on the hybridizability of the transported target DNA to the specific capture DNA at the test site. As to transport, the conductivity generally correlates with transport under the same field conditions.  $\beta$ -Alanine, Taurine and Cysteine show excellent transport, Histidine shows good transport, and Lysine and NaPO<sub>4</sub> show fair transport. The DNA hybridization sensitivity is reported for "normal DNA" which has negatively charged polyanionic phosphate backbone. In addition to the hybridization sensitivities, Table 2 also reports the sensitivity for the streptavidin/biotin DNA probe capture affinity.

Table 2 clearly shows the correlation of DNA transport (accumulation) with low conductivity ( $\beta$ -Alanine, Taurine, Cysteine, Histidine). The table shows good

<sup>1/</sup> 20mM NaPO<sub>4</sub> adjusted to pH 7.4.

sensitivity for the streptavidin/biotin probe affinity reaction using  $\beta$ -Alanine, Cysteine, and Histidine. As reflected in the sensitivity data in Table 2, Histidine provides over four orders of magnitude better hybridization efficiency than either Cysteine or other buffers, such as 20 mM  $\text{NaPO}_4$ . The improvement relative to Cysteine is at least a factor of 10, more especially a factor of  $10^2$ , and most especially at least a factor of  $10^4$ . Most importantly Table 2 shows that the DNA hybridization sensitivity (efficiency) is very good for the Histidine buffer. Thus of all the zwitterionic amino acid buffers presently tested, Histidine is the only one which provides both good transport and good DNA/DNA hybridization efficiency.

It is believed that the low conductivity of the Histidine buffer system accounts for the rapid DNA transport (accumulation). There are several possible explanations as to why the Histidine buffer produces relatively efficient DNA/DNA hybridization. One advantage may be the good buffering capacity of Histidine. With its pI at 7.47, Histidine will buffer well under both acidic or basic conditions (see A.L. Lehninger, Biochemistry, 2ed, Worth Publishers, New York, 1975, Fig. 4-9 on page 80). The APEX chip produces acid at the positive electrode where the DNA is accumulated for hybridization, and Histidine may effectively buffer these conditions. More importantly, under these acidic conditions (pH<5) the protonation of the imidazole group on the Histidine begins to convert the molecule into a dicationic species. It may be the case that this dicationic species with a positively charged  $\alpha$ -amino group and a positively charge imidazole group may help to promote hybridization and stabilize the DNA/DNA hybrids formed at the positive electrode on the APEX chip. Cations, dications, and polycations are known to help stabilize DNA/DNA hybrids by reducing the repulsion of the negatively charged phosphate backbones on the double-stranded DNA structure. It is also possible

that the DNA/DNA/Histidine may also form some type of stabilizing adduct from other electrochemical products being produced at the positive electrode (hydrogen peroxide, etc.)

5        While the instant embodiment utilizes naturally occurring Histidine, this invention is fully applicable to other natural or synthetic compounds which have good buffering capacity, low conductivity (or zwitterionic characteristics) and have properties which allow DNA  
10 hybridization to be stabilized by charge stabilization or adduct formation.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be readily  
15 apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims

1. A method for transporting and hybridizing target nucleic acids in a microelectronic device having at least one test site bearing a capture nucleic acid,  
5 comprising the steps of:
- (1) applying a low conductance buffer to the device,
  - (2) applying current to the device to produce an electric field at the test site,
  - 10 (3) transporting the target nucleic acids to the test site, and
  - (4) hybridizing the target nucleic acids to the capture nucleic acid at the test site with a hybridization efficiency which is at  
15 least a factor of 10 times greater than for Cysteine under the same conditions.
2. The method of claim 1 wherein the low conductivity buffer is a zwitterionic buffer.
3. The method of claim 2 wherein the zwitterionic  
20 buffer includes histidine.
4. The method of claim 3 wherein the histidine was prepared at a concentration of about 10-100 mM.
5. The method of claim 3 wherein the histidine was prepared at or about the isoelectric point.
- 25 6. The method of claim 1 wherein the isoelectric point is about pH 7.47.
7. The method of claim 1 wherein the buffer entity stabilizes hybridization between the target nucleic acids and the capture nucleic acid.

8. The method of claim 7 wherein the buffer entity is a natural compound with low conductivity.

9. The method of claim 7 wherein the buffer entity is a natural, zwitterionic compound.

5 10. The method of claim 7 wherein the buffer entity is a synthetic compound with low conductivity.

11. The method of claim 7 wherein the buffer entity is a synthetic, zwitterionic compound.

10 12. The method of claim 1 wherein the hybridization efficiency is at least a factor of 100 times greater than for Cysteine under the same conditions.

13. The method of claim 1 wherein the hybridization efficiency is at least a factor of 1,000 times greater than for Cysteine under the same conditions.

15 14. The method of claim 1 wherein the hybridization efficiency is at least a factor of approximately 50,000 times greater than for Cysteine under the same conditions.

15 15. The method of claim 1 wherein the buffer entity reduces repulsion between the capture nucleic acid and the target nucleic acids.

16. The method of claim 1 wherein the buffer reduces adduct formation between the capture nucleic acid and the target nucleic acids.

25 17. A method for enhancing the electrophoretic transport and hybridization efficiency of target nucleic acids in a microelectronic hybridization device including a microlocation test site having a capture nucleic acid, comprising the steps of:

applying a low conductivity buffer to the device,

5 applying power to the device to cause electrophoretic transport and accumulation of the target nucleic acids at a microlocation test site on the device, and

hybridizing the target nucleic acids with an efficiency which is at least a factor of 10 times greater than for Cysteine under the same conditions.

10 18. The method of claim 17 wherein the low conductivity buffer is a zwitterionic buffer.

19. The method of claim 18 wherein the zwitterionic buffer includes histidine.

15 20. The method of claim 19 wherein the histidine was prepared at a concentration of about 10-100 mM.

21. The method of claim 19 wherein the histidine was prepared at or about the isoelectric point.

22. The method of claim 17 wherein the isoelectric point is about pH 7.47.

20 23. The method of claim 17 wherein the buffer entity stabilizes hybridization between the target nucleic acids and the capture nucleic acid.

24. The method of claim 23 wherein the buffer entity is a natural compound with low conductivity.

25 25. The method of claim 23 wherein the buffer entity is a natural, zwitterionic compound.

26. The method of claim 23 wherein the buffer entity is a synthetic compound with low conductivity.

27. The method of claim 23 the buffer entity is a synthetic, zwitterionic compound.

28. The method of claim 17 wherein the hybridization efficiency is at least a factor of 100 times greater than  
5 for Cysteine under the same conditions.

29. The method of claim 17 wherein the hybridization efficiency is at least a factor of 1,000 times greater than for Cysteine under the same conditions.

30. The method of claim 17 wherein the hybridization  
10 efficiency is at least a factor of approximately 50,000 times greater than for Cysteine under the same conditions.

31. The method of claim 17 wherein the buffer entity reduces repulsion between the capture nucleic acid and the target nucleic acids.

15 32. The method of claim 17 wherein the buffer reduces adduct formation between the capture nucleic acid and the target nucleic acids.--

1 / 1




Fig. 1



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/14489

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet

US CL : 204/450, 468; 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 204/450,468;435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAPLUS, USPAT, JPOABS, WPIDS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,936,963 A (MANDECKI ET AL) 26 June 1990 (26/06/90) see entire document.	1-11
---		-----
Y		1-11
Y	US 5,436,129 A (STAPLETON) 25 July 1995 (25/07/95) see entire document.	1-11
E	US 5,593,838 A (ZANZUCCHI ET AL) 14 January 1997 (19/01/97) see entire document.	1-11

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* B* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 SEPTEMBER 1997

Date of mailing of the international search report

05 DEC 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer

JOHN S. STARSIAK JR.

Telephone No. (703) 308-0661

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/14489

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

G01N 27/26, 27/447; C12N 15/00